Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
NCT03240861 · Jonsson Comprehensive Cancer Center · PHASE1 · terminated · last registry update 2023-11-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow accrual” | – | Registry record, Jonsson Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-26Results posted on the registry: Inge Marie Svane, Autologous tumor-infiltrating lymphocytes + Ipilimumab (NCT03296137)
- 2024-10-22Also stopped (terminated): Armando Torres Ramírez, Tacrolimus with rapid steroid withdrawal + Tacrolimus with steroids minimization (NCT01002339)
- 2024-10-08Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + Autologous CD8+ Melanoma Specific T Cells (NCT02027935)
- 2024-10-08Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes (NCT01740557)
- 2024-10-03Also stopped (terminated): Wake Forest University Health Sciences, Tumor Infiltrating Lymphocytes (TIL) (NCT00863330)
- 2024-09-19Also stopped (terminated): Roswell Park Cancer Institute, Aldesleukin + Autologous NY-ESO-1-specific CD8-positive T Lymphocytes (NCT03691376)
- 2024-07-24Results posted on the registry: Carman Giacomantonio, Aldesleukin (NCT03233828)
- 2024-07-24Also stopped (terminated): Carman Giacomantonio, Aldesleukin (NCT03233828)
- 2024-06-13Results posted on the registry: ADC Therapeutics S.A., ADCT-301 + Pembrolizumab (NCT03621982)
- 2024-06-13Also stopped (terminated): ADC Therapeutics S.A., ADCT-301 + Pembrolizumab (NCT03621982)
- 2024-05-22Also stopped (withdrawn): Jay S. Skyler, ILT-101 (Aldesleukin; IL-2) (NCT03243058)
- 2024-04-08Results posted on the registry: City of Hope Medical Center, Aldesleukin (NCT03007238)
- 2024-03-28Results posted on the registry: ADC Therapeutics S.A., Camidanlumab Tesirine (NCT04052997)
- 2024-03-12Also stopped (withdrawn): National Cancer Institute (NCI), Fludarabine + Cyclophosphamide (NCT04102436)
- 2024-01-17Also stopped (terminated): Washington University School of Medicine, Fludarabine + Cyclophosphamide (NCT01898793)
- 2023-12-22Results posted on the registry: Massachusetts General Hospital, Alpha 1-Antitrypsin + Thymoglobulin (NCT02464878)
- 2023-12-05Results posted on the registry: Clinigen, Inc., High Dose Interleukin-2 + Ipilimumab (NCT01856023)
- 2023-12-05Also stopped (terminated): Clinigen, Inc., High Dose Interleukin-2 + Ipilimumab (NCT01856023)
- 2023-12-04Also stopped (terminated): Mario Negri Institute for Pharmacological Research, Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil + Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil (NCT00752479)
- 2023-11-07Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + Allogeneic CD56-positive CD3-negative Natural Killer Cells (NCT01823198)
- 2023-09-21Also stopped (terminated): Fate Therapeutics, FT516 + Avelumab (NCT04551885)
- 2023-08-15Also stopped (withdrawn): University of Nebraska, a drug against IL2RA (NCT02409147)
- 2023-08-04Results posted on the registry: Albert Einstein College of Medicine, Aldesleukin + Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (NCT02774291)
- 2023-08-04Also stopped (terminated): Albert Einstein College of Medicine, Aldesleukin + Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (NCT02774291)
- 2023-08-03Also stopped (terminated): Rutgers, The State University of New Jersey, Aldesleukin + Pembrolizumab (NCT02748564)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision